A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2 | |
Knox, J.; Cheng, A.; Cleary, S.; Galle, P.; Kokudo, N.; Lencioni, P.; Park, J.; Zhou, J.; Mann, H.; Morgan, S. | |
2019 | |
卷号 | 30 |
会议录 | ANNALS OF ONCOLOGY
![]() |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 0923-7534 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3596094 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Knox, J.,Cheng, A.,Cleary, S.,et al. A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论